Imed and Ivac Join Forces
The deal couldn't have come too soon. For all the interest in IVAC and IMED, the infusion market is becoming increasingly competitive, with smaller companies slowly being squeezed out of the market by industry giants, Abbott and Baxter.
You may also be interested in...
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.